Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony F Shields

Showing results (51-60 of 186) with videos related to

Pageof 19
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 11, 2008
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registryBruce E Hillner, Barry A Siegel, Anthony F Shields, et al.
Case Reports in Oncology|August 26, 2010
Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric CancerMohammad Mobayed, Lance K Heilbrun, Anthony F Shields, et al.
Molecular Imaging and Biology|October 11, 2003
High 2-deoxy-2-[18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumorSubhash Chander, Eser Lay Ergun, Harry T Chugani, et al.
Investigational New Drugs|August 29, 2006
Phase II trial of interferon and thalidomide in metastatic renal cell carcinomaUlka N Vaishampayan, Lance K Heilbrun, Anthony F Shields, et al.
Journal of Gastrointestinal Oncology|January 18, 2020
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancersKabir Mody, Jason Starr, Michelle Saul, et al.
American Journal of Clinical Oncology|January 3, 2019
Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer CenterKevin J Zhang, Greg Dyson, Joshua L Gatz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2017
Intended Versus Inferred Treatment After <sup>18</sup>F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET RegistryBruce E Hillner, Lucy Hanna, Rajesh Makineni, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2010
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapyNazik Hammad, Lance K Heilbrun, Philip A Philip, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2012
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohortsBruce E Hillner, Barry A Siegel, Lucy Hanna, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2017
Hospice Admission and Survival After <sup>18</sup>F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET RegistryIlana F Gareen, Bruce E Hillner, Lucy Hanna, et al.
Pageof 19

Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 11, 2008
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registryBruce E Hillner, Barry A Siegel, Anthony F Shields, et al.
Case Reports in Oncology|August 26, 2010
Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric CancerMohammad Mobayed, Lance K Heilbrun, Anthony F Shields, et al.
Molecular Imaging and Biology|October 11, 2003
High 2-deoxy-2-[18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumorSubhash Chander, Eser Lay Ergun, Harry T Chugani, et al.
Investigational New Drugs|August 29, 2006
Phase II trial of interferon and thalidomide in metastatic renal cell carcinomaUlka N Vaishampayan, Lance K Heilbrun, Anthony F Shields, et al.
Journal of Gastrointestinal Oncology|January 18, 2020
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancersKabir Mody, Jason Starr, Michelle Saul, et al.
American Journal of Clinical Oncology|January 3, 2019
Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer CenterKevin J Zhang, Greg Dyson, Joshua L Gatz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2017
Intended Versus Inferred Treatment After <sup>18</sup>F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET RegistryBruce E Hillner, Lucy Hanna, Rajesh Makineni, et al.
Asia-Pacific Journal of Clinical Oncology|June 23, 2010
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapyNazik Hammad, Lance K Heilbrun, Philip A Philip, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2012
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohortsBruce E Hillner, Barry A Siegel, Lucy Hanna, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 30, 2017
Hospice Admission and Survival After <sup>18</sup>F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET RegistryIlana F Gareen, Bruce E Hillner, Lucy Hanna, et al.
Pageof 19